These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 6772357)

  • 41. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contemporary Management of Polycystic Ovarian Syndrome.
    Zimmerman LD; Setton R; Pereira N; Rosenwaks Z
    Clin Obstet Gynecol; 2019 Jun; 62(2):271-281. PubMed ID: 30994482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.
    Adams J; Polson DW; Franks S
    Br Med J (Clin Res Ed); 1986 Aug; 293(6543):355-9. PubMed ID: 3089520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ovarian response patterns to human menopausal gonadotropin in mixed hyperandrogenemia.
    Hamori M; Török A; Zwirner M; Tinneberg HR
    Acta Endocrinol (Copenh); 1990 Dec; 123(6):598-602. PubMed ID: 2149487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial.
    Bayram N; van Wely M; Kaaijk EM; Bossuyt PM; van der Veen F
    BMJ; 2004 Jan; 328(7433):192. PubMed ID: 14739186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
    Nestler JE
    Semin Reprod Endocrinol; 1997 May; 15(2):111-22. PubMed ID: 9165656
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polycystic ovarian disease.
    Duignan NM
    Br J Obstet Gynaecol; 1976 Aug; 83(8):593-602. PubMed ID: 133709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endocrine function in human obesity.
    Glass AR; Burman KD; Dahms WT; Boehm TM
    Metabolism; 1981 Jan; 30(1):89-104. PubMed ID: 6780754
    [No Abstract]   [Full Text] [Related]  

  • 50. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
    Nardo LG; Patchava S; Laing I
    Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subclinical hypothyroidism: a determinant of polycystic ovary syndrome.
    Ghosh S; Kabir SN; Pakrashi A; Chatterjee S; Chakravarty B
    Horm Res; 1993; 39(1-2):61-6. PubMed ID: 8406342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implications of ultrasonically diagnosed polycystic ovaries. I. Correlations with basal hormonal profiles.
    Abdel Gadir A; Khatim MS; Mowafi RS; Alnaser HM; Muharib NS; Shaw RW
    Hum Reprod; 1992 Apr; 7(4):453-7. PubMed ID: 1522185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypothalmic-pituitary relationships in the polycystic ovary syndrome serum gonadotrophin levels following injection of oestradiol benzoate.
    Shaw RW; Duignan NM; Butt WR; Edwards RL; London DR
    Br J Obstet Gynaecol; 1975 Dec; 82(12):952-7. PubMed ID: 1106757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hyperandrogenaemia and the ovary.
    Norman RJ
    Mol Cell Endocrinol; 2002 May; 191(1):113-9. PubMed ID: 12044925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome.
    Bützow TL; Kettel LM; Yen SS
    Fertil Steril; 1995 Jun; 63(6):1200-3. PubMed ID: 7750589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pathogenesis of polycystic ovary syndrome].
    Koreneva GP; Shikaeva FV; Efimenko NF
    Akush Ginekol (Mosk); 1982 Feb; (2):21-3. PubMed ID: 6805352
    [No Abstract]   [Full Text] [Related]  

  • 59. Radioimmunoassay of plasma LH and FSH in selected endocrine disorders.
    Isidori A; Fraioli F; Conti C
    Folia Endocrinol; 1972 Apr; 25(2):127-34. PubMed ID: 4679261
    [No Abstract]   [Full Text] [Related]  

  • 60. The significance of anthropometric and endocrine parameters in ovulation induction with clomiphene citrate in women with polycystic ovary syndrome.
    Akpinar F; Dilbaz B; Cırık DA; Yilmaz S; Kiykac S; Karahanoglu E; Mollamahmutoglu L
    Saudi Med J; 2016 Nov; 37(11):1272-1275. PubMed ID: 27761570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.